Business Highlights - OmniAb has 104 active partners as of September 30, 2025 [13] - The company has 399 active programs as of September 30, 2025, a net addition of 36 programs year-to-date [16, 18] - There are 32 active clinical programs and approved products as of September 30, 2025 [26] - OmniAb is launching OmniUltra in December, a new technology for antibody and peptide therapeutics discovery [11, 41] Financial Performance - Q3 2025 total revenue was $22 million, compared to $42 million in Q3 2024 [65] - License and milestone revenue decreased to $06 million in Q3 2025 from $14 million in Q3 2024 [65] - Service revenue decreased to $12 million in Q3 2025 from $25 million in Q3 2024 [65] - Royalty revenue increased to $04 million in Q3 2025 from $03 million in Q3 2024 [65] - Research and Development expenses decreased to $104 million in Q3 2025 from $133 million in Q3 2024 [65] - Net loss was ($165) million in Q3 2025, compared to ($164) million in Q3 2024 [65] Financial Guidance - The company expects 2025 revenue to be in the range of $18 to $22 million [67] - The company expects 2025 operating expense to be in the range of $82 to $86 million [67]

Q2 2025 Highlights - OmniAb sold and installed xPloration instrument shortly after launch, with strong partner interest[11] - Partner pipeline advancement continued[11] - Deal flow and new partner additions are accelerating[11] - Outlook for 2025 remains on track[11] Partnership and Programs - The company has 100 active partners as of June 30, 2025, with 54% in the US, 25% in Europe, 20% in Asia, and 1% in the Middle East[12, 13] - Active programs totaled 381 as of June 30, 2025, a net addition of 18 programs year-to-date[16, 18] - Approximately 99% of active programs have contracted future economics to OmniAb[21] - Antibody Standard Licenses account for 90% of active programs[20] - Total remaining milestones for Antibody Standard Licenses are greater than $3 billion, with an average royalty rate of 3.36%[21] - Post-discovery stage programs have grown by 22% over the last 12 months[24] - There are 32 active clinical programs and approved products as of June 30, 2025[27, 29] Financial Performance - Q2 2025 total revenue was $3.9 million, compared to $7.6 million in Q2 2024[49, 54] - Q2 2025 license and milestone revenue was $1.2 million, down from $3.1 million in Q2 2024[54] - Q2 2025 service revenue was $1.9 million, down from $4.2 million in Q2 2024[54] - Q2 2025 xPloration revenue was $0.6 million[54] - Q2 2025 royalty revenue was $0.1 million, down from $0.3 million in Q2 2024[54] - Q2 2025 net loss was $15.9 million, compared to a net loss of $13.6 million in Q2 2024[54] 2025 Guidance - Revenue is expected to be in the range of $20 million to $25 million[57] - Operating expense is expected to be in the range of $85 million to $90 million[57]